6、肾脏SGLT2抑制剂如达格列净,恩格列净,坎格列净,依格列净等。7、胰岛素以及胰岛素类似物,根据起效和有效作用时间分为餐时胰岛素和基础胰岛素。8、GLP-1受体激动剂包括基于Exendin-4的治疗药物艾塞那肽和人GLP-1类似物利拉鲁肽。9、降血糖中药。三、降血糖药物选用的原则以上九大类不同作用机制的降血糖药物...
SGLT2 Inhibitorsblock the reabsorption of glucose in the kidneys, causing it to be released in urine and lower blood glucose levels. Examples: canagliflozin (Invokana), dapagliflozin (Farxiga) Alpha-glucosidase inhibitorsblock the digestion ofcarbohydrates(simple sugars) and slow the rise in blood glu...
Prescription Drugs: Rapamycin –broadly for longevity Pregabalin & Trazodone –for improving sleep architecture Ezetimibe, Rapatha & Bempedoic acid –for reducing cardiovascular disease risk SGLT2 Inhibitor –blocks the re-uptake of glucose For a detailed breakdown of what else this article covers, see...
Canagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. Canagliflozin is chemically known as (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4methylphenyl]-D-glucitol ...
Mandrola's Top 10 Cardiology Stories of 2021 Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research. theheart.org on Medscape, December 15, 2021 ...
Obesity, a driver of inflammation, is prevalent in patients with HFpEF. Ileana Pina asks Ambarish Pandey about GLP-1 agonists and SGLT2 inhibitors in HFpEF. Are these drugs anti-inflammatory? theheart.org on Medscape, July 27, 2023 3 Previous...
Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II (SGLT2) inhibitor, in animals and humans. Drug Metab Dispos. 38(3):405-14, 20...
This study aimed to examine the reporting quality of existing economic evaluations for negotiated glucose-lowering drugs (GLDs) included in China National Reimbursement Drug List (NRDL) using the Consolidated Health Economic Evaluation Reporting Standard
trials for all novel antidiabetic agents [i.e., dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2is)] with the aim to assess the CV safety of these drugs beyond glycemic control....